209 related articles for article (PubMed ID: 30095158)
1. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.
Rauert-Wunderlich H; Mottok A; Scott DW; Rimsza LM; Ott G; Klapper W; Unterhalt M; Kluin-Nelemans HC; Hermine O; Hartmann S; Thorns C; Rymkiewicz G; Holte H; Dreyling M; Hoster E; Rosenwald A
Br J Haematol; 2019 Feb; 184(4):616-624. PubMed ID: 30095158
[TBL] [Abstract][Full Text] [Related]
2. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Holte H; Beiske K; Boyle M; Trøen G; Blaker YN; Myklebust J; Kvaløy S; Rosenwald A; Lingjaerde OC; Rimsza LM; Smeland EB; Scott DW; Kolstad A
Br J Haematol; 2018 Oct; 183(2):225-234. PubMed ID: 30080252
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
4. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
5. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.
Scott DW; Abrisqueta P; Wright GW; Slack GW; Mottok A; Villa D; Jares P; Rauert-Wunderlich H; Royo C; Clot G; Pinyol M; Boyle M; Chan FC; Braziel RM; Chan WC; Weisenburger DD; Cook JR; Greiner TC; Fu K; Ott G; Delabie J; Smeland EB; Holte H; Jaffe ES; Steidl C; Connors JM; Gascoyne RD; Rosenwald A; Staudt LM; Campo E; Rimsza LM;
J Clin Oncol; 2017 May; 35(15):1668-1677. PubMed ID: 28291392
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
7. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
9. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
[TBL] [Abstract][Full Text] [Related]
10. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
11. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
[TBL] [Abstract][Full Text] [Related]
12. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA; Rosenthal A; Robetorye RS; Mwangi R; Maurer M; Villa D; McDonnell T; Feldman A; Cohen JB; Habermann T; Campo E; Clot G; Bühler MM; Kulis M; Martin-Subero JI; Giné E; Cook JR; Hill B; Raess PW; Beiske KH; Reichart A; Hartmann S; Holte H; Scott D; Rimsza L
Br J Haematol; 2024 Jan; 204(1):160-170. PubMed ID: 37881141
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
[TBL] [Abstract][Full Text] [Related]
15. PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma.
Zhang X; Han Y; Nie Y; Jiang Y; Sui X; Ge X; Liu F; Zhang Y; Wang X
J Mol Med (Berl); 2023 May; 101(5):595-606. PubMed ID: 37126184
[TBL] [Abstract][Full Text] [Related]
16. Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma.
Ramsower CA; Maguire A; Robetorye RS; Feldman AL; Syrbu SI; Rosenthal AC; Rimsza LM
J Hematop; 2020 Dec; 13(4):231-238. PubMed ID: 33193905
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
18. Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score.
Salim R; Husby S; Winther Eskelund C; Scott DW; Holte H; Kolstad A; Räty R; Ek S; Jerkeman M; Geisler C; Sommer Kristensen L; Dahl M; Grønbæk K
Leuk Lymphoma; 2023; 64(8):1414-1423. PubMed ID: 37259807
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
20. TCL1 expression predicts overall survival in patients with mantle cell lymphoma.
Shin SJ; Roh J; Cha HJ; Choi YD; Kim JM; Min SK; Kim JE; Eom DW; Lee H; Kim HJ; Yoon DH; Suh C; Huh J
Eur J Haematol; 2015 Dec; 95(6):583-94. PubMed ID: 25688912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
